GCAN - The Greater Cannabis Company, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0050
-0.0005 (-8.42%)
At close: 2:49PM EDT
Stock chart is not supported by your current browser
Previous Close0.0055
Open0.0060
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0046 - 0.0070
52 Week Range0.0037 - 0.3400
Volume2,473,467
Avg. Volume579,616
Market Cap185,979
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GCAN Receives Purchase Order for 125,000 Units of its Oral Cannabis Patch from Symtomax
    GlobeNewswire

    GCAN Receives Purchase Order for 125,000 Units of its Oral Cannabis Patch from Symtomax

    Greater Cannabis Company (GCAN), an innovator in the development and commercialization of cannabinoid delivery systems and cannabinoids products is proud to announce that it has received a purchase order for 125,000 units of its eluting transmucosal patch. GCAN’s oral patch has been shown in clinical studies to be a safe and effective way to deliver lower doses of pharmaceutical actives, while achieving high levels of bioavailability. The purchase order came via Greater Cannabis’ European distribution partner Symtomax.

  • Greater Cannabis Company Advances CBD Study With Researchers From Israel Cannabis Research Center
    GlobeNewswire

    Greater Cannabis Company Advances CBD Study With Researchers From Israel Cannabis Research Center

    Greater Cannabis Company (GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems and cannabinoids products is proud to announce that is has advanced its cannabidiol research study with researchers from Hadassah Hebrew University Hospital and Research Center. The first cooperative effort involves studying different formulations of cannabidiol (CBD) using Greater Cannabis’ innovative delivery platform, which has been successful in achieving 40-50% bioavailability using different active pharmaceutical ingredients (APIs). The study will help further substantiate the significance of the eluting transmucosal patch (ETP) platform, and advance a number of ongoing discussions the Company has with pharmaceutical and cannabis companies.

  • Former Portugal State Secretary of Health Joins Greater Cannabis Company’s European Partner, Symtomax
    GlobeNewswire

    Former Portugal State Secretary of Health Joins Greater Cannabis Company’s European Partner, Symtomax

    Greater Cannabis Company (GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, is proud to announce that its European-based partner Symtomax, has appointed former Portugal State Secretary of Health to its board of directors. Symtomax currently owns one of the largest legal cannabis cultivation areas in Europe, with a planned production facility site in Portugal totaling 1,830,000 square meters. In addition to its 40 years in medical cannabis, it has extensive international experience in operations, capital markets, corporate finance, law, and healthcare services.

  • The Greater Cannabis Company Expands CBD Delivery Portfolio With Newly Developed Transdermal Patch
    GlobeNewswire

    The Greater Cannabis Company Expands CBD Delivery Portfolio With Newly Developed Transdermal Patch

    OTCQB: GCAN), a biopharmaceutical market leader and innovator in the development and commercialization of cannabinoid delivery systems is pleased to update its shareholders that is has successfully developed and tested a transdermal cannabidiol delivery patch. The transdermal patch is a new product that utilizes some of the same proprietary delivery enhancing capabilities that GCAN has been successful in implementing with its eluting transmucosal patch (oral strip). The transdermal application has broad application, and can be loaded with CBD as well as other active pharmaceutical ingredients (APIs).

  • GCANRx offers oral patch with cannabinoid, as vaping-related illnesses increase
    Yahoo Finance Video

    GCANRx offers oral patch with cannabinoid, as vaping-related illnesses increase

    Vaping related illnesses continue to rise, prompting the FDA and CDC to launch an investigation. Meanwhile, GCANRx thinks that it has a possible solution, a patch that releases a certain amount of cannabinoid each use. GCANRx CEO Aitan Zacharin joins On The Move to discuss.

  • Greater Cannabis CEO to be Interviewed Today on Yahoo Finance Live at 12:40pm EST
    GlobeNewswire

    Greater Cannabis CEO to be Interviewed Today on Yahoo Finance Live at 12:40pm EST

    CEO will appear on the On The Move show to discuss Company’s technology as a high-tech alternative to vaping devices, why the GCANRx patch is safer, and what’s in the pipeline for the future. BALTIMORE, MD, Sept. 23, 2019 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, is scheduled to be featured in a live interview today at 12:40pm EST on the Yahoo Finance News Network’s On The Move Show. During today’s segment, the Company’s Chief Executive Officer, Aitan Zacharin, is expected to discuss the GCANRx delivery technology as a high-tech alternative to vaping devices and other methods of administration of cannabis, why the GCANRx patch is safer, how it differs from other delivery systems, and how it works.

  • The Greater Cannabis Company Provides Corporate Update to Shareholders
    GlobeNewswire

    The Greater Cannabis Company Provides Corporate Update to Shareholders

    OTCQB: GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems is pleased to update its shareholders on operational aspects of the business. Over the last few months the Company has been successful in achieving numerous milestones in the advancement of its business strategy, as outlined in this communication. The Company has finalized and executed a definitive agreement with Symtomax, a leading licensed cannabis cultivation company with the largest outdoor grow facilities in Europe.

  • Greater Cannabis Company Signs letter of intent (LOI) with RST, Inc.
    GlobeNewswire

    Greater Cannabis Company Signs letter of intent (LOI) with RST, Inc.

    Greater Cannabis Company (GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, has announced today a letter of intent (LOI) with RST, Inc. RST is a top global manufacturer of private label skin care products with nearly a billion dollars in products sold worldwide, and more than twenty years of success. Under the agreement, RST will integrate Greater Cannabis Company’s proprietary CBD formulation into its skincare products, with both companies targeting distribution of the CBD-infused products developed across their multinational distribution channels.

  • GREATER CANNABIS COMPANY PARTNERS WITH SYMTOMAX® TO EXPAND ACROSS EUROPE, THE MIDDLE EAST AND AFRICA
    GlobeNewswire

    GREATER CANNABIS COMPANY PARTNERS WITH SYMTOMAX® TO EXPAND ACROSS EUROPE, THE MIDDLE EAST AND AFRICA

    Greater Cannabis Company (GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, today announced it has entered into a letter of agreement (LOI) with European-based Symtomax, a licensed group on medical cannabis cultivation, research and distribution with over 40 years of experience in the medical cannabis industry. Effective immediately, Symtomax will distribute on a white-label basis Greater Cannabis Company’s oral eluting patch, transdermal patch, and other proprietary technologies and products across its distribution network that spans across Europe, the Middle East and Africa. “Delivering on our commitment to spearhead our expansion plans required an alternative delivery means of legal cannabis. We were drawn to the Greater Cannabis Company’s proprietary and proven technologies, product portfolio and market leadership,” said Paul Segal, Chief Executive Officer of Symtomax.

  • Greater Cannabis CEO to be Interviewed Today By Cheddar Financial News Live From the New York Stock Exchange
    GlobeNewswire

    Greater Cannabis CEO to be Interviewed Today By Cheddar Financial News Live From the New York Stock Exchange

    BALTIMORE, MD, May 01, 2019 (GLOBE NEWSWIRE) --   Greater Cannabis Company (GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, is scheduled to be featured in a live interview today at 1:10 pm EST on the Cheddar Financial News Network on the floor of the New York Stock Exchange (NYSE) during trading hours. During today’s segment, the Company’s Chairman and Chief Executive Officer, Aitan Zacharin, is expected to provide a brief summary of the history of Greater Cannabis Company, why and how it was formed and, in particular, its proprietary cannabinoid delivery system, which is anticipated to become one of the most disruptive technologies in cannabis industry since its legalization.  Please note the interview can be viewed on the Cheddar.tv website and other services the network streams to., which can be found on its site.

  • GREATER CANNABIS COMPANY LICENSES CBD PATCH TECHNOLOGY TO MAJOR BRAZILIAN RETAIL PHARMACY COMPANY
    GlobeNewswire

    GREATER CANNABIS COMPANY LICENSES CBD PATCH TECHNOLOGY TO MAJOR BRAZILIAN RETAIL PHARMACY COMPANY

    The Greater Cannabis Company (GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, today announced it has entered into a letter of agreement (LOI) with a major Brazilian retail pharmacy company, CBR Participacoes SA, to market Greater Cannabis Company’s eluting patch technology for cannabis in Brazil. As part of the agreement, CBR Participacoes will distribute the technology to its network of 300 pharmacies and more than 1,500 point-of-sale retailers in the country, serving the Brazil’s growing demand and market for cannabis products.

  • Greater Cannabis Company Partners with Allume Cosmeticos To Develop New Cosmetics Line
    GlobeNewswire

    Greater Cannabis Company Partners with Allume Cosmeticos To Develop New Cosmetics Line

     BALTIMORE, MD, April 11, 2019 (GLOBE NEWSWIRE) --  Greater Cannabis Company (GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, today announced a letter of agreement (LOI) with leading Brazilian beauty and personal care company Allume Cosmeticos. Under the terms of the agreement, Greater Cannabis Company will customize formulations and incorporate its proprietary technology to infuse pharmaceutical-grade cannabidiol (CBD) into Allume’s new line of CBD-based cosmetic products, empowering Allume to market and distribute CBD-infused beauty and personal care for its retail partners, distributors and millions of customers. CBD has shown multiple beauty and personal care benefits, ranging from antioxidants for anti-aging to anti-inflammatory for acne and other treatments.

  • The Beauty of CBD: Cannabis Companies Shift Focus towards Beauty and Wellness  
    GlobeNewswire

    The Beauty of CBD: Cannabis Companies Shift Focus towards Beauty and Wellness  

    Investorideas.com, a leading investor news resource covering cannabis stocks, releases a snapshot looking at the many cannabis companies looking into the CBD beauty and wellness sector and why this sector is gaining such momentum. According to one report from the GlobalWellnessInstitute, “a wellness mindset is starting to permeate the global consumer consciousness, affecting people’s daily decision-making – whether food purchases, a focus on mental wellness and reducing stress, incorporating movement into daily life, environmental consciousness, or their yearning for connection and happiness,” noted Katherine Johnston, senior research fellow, GWI. This change in mindset combined with growing interest from large retailers, most recently CVS and Walgreens, is making many companies invest in beauty and wellness.

  • Greater Cannabis Company Announces Expansion Into CBD Cosmetics And Beauty Market
    GlobeNewswire

    Greater Cannabis Company Announces Expansion Into CBD Cosmetics And Beauty Market

    Greater Cannabis Company (GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, today announced its expansion into the cannabidiol (CBD) beauty, cosmetics and self-care markets. In addition to its highly bioavailable, orally dissolving transmucosal patch, the Company is now formulating and commercializing a new line of products for CBD-infused cosmetics and skincare applications. “Consumer demand for CBD-infused beauty products has prompted major retailers such as Walgreens, Sephora and CVS, and major cosmetic brands like Estee Lauder, to move into this emerging sector,” said Aitan Zacharin, Chief Executive Officer of Greater Cannabis Company.

  • GREATER CANNABIS TO BEGIN CLINICAL STUDY OF CBD ABSORPTION THROUGH ITS MULTIFUNCTIONAL, MULTILAYER INTRA-ORAL DRUG DELIVERY TECHNOLOGY
    GlobeNewswire

    GREATER CANNABIS TO BEGIN CLINICAL STUDY OF CBD ABSORPTION THROUGH ITS MULTIFUNCTIONAL, MULTILAYER INTRA-ORAL DRUG DELIVERY TECHNOLOGY

    GREATER CANNABIS COMPANY (GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, has announced today that it will launch a new clinical study to determine cannabidiol (CBD) absorption using its patented eluting patch technology. The new study will help drive the continued development and success of its delivery system and expand its commercialization to LPs, consumer product and pharmaceutical companies.

  • The Greater Cannabis Company Announces Uplisting To New Market Tier
    GlobeNewswire

    The Greater Cannabis Company Announces Uplisting To New Market Tier

    The Greater Cannabis Company, Inc. (GCAN) (“the Company”), a biopharmaceutical company focused on development and commercialization of innovative delivery systems for the Cannabis market, today announced that shares of its common stock were approved for quotation on the OTCQB® Venture Market. To qualify for this market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and be current in their disclosure. The Company believes that the move to the OTCQB will provide enhanced investor benefits including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance requirements.

  • Cannabis Companies Expanding Global Footprint; The Greater Cannabis Company Inc. (OTC:GCAN), Aphria, Canopy Growth and AgraFlora Organics
    GlobeNewswire

    Cannabis Companies Expanding Global Footprint; The Greater Cannabis Company Inc. (OTC:GCAN), Aphria, Canopy Growth and AgraFlora Organics

    Investorideas.com, a leading investor news resource covering cannabis stocks releases a snapshot looking at the global expansion of the cannabis industry and the companies looking at new international markets as regulations change. As new international markets being to open, both cannabis giants as well as smaller cannabis technology companies are now making the necessary preparations to enter this international space. The Greater Cannabis Company, Inc. (OTC:GCAN), recently announced that it has entered into a letter of intent with iCAN Cannabis to expand distribution of its eluting patch platform into key global markets.

  • The Greater Cannabis Company Announces Distribution Agreement With Leading Global Cannabis Company iCAN: Israel Cannabis Ltd.
    GlobeNewswire

    The Greater Cannabis Company Announces Distribution Agreement With Leading Global Cannabis Company iCAN: Israel Cannabis Ltd.

    The Greater Cannabis Company, Inc. (GCAN) (“the Company”), a biopharmaceutical company focused on development and commercialization of innovative delivery systems for the Cannabis market is pleased to announce that it has entered into a letter of intent with iCAN Cannabis to expand distribution of its eluting patch platform into key global markets. The agreement with iCAN will include commercial ready formulations to meet medical and recreational market demands. Distribution and marketing rights for iCAN will include Israel, Australia, South Africa, Netherlands, South Africa, Mexico, Colombia, Panama, Germany, Austria, Switzerland, Malta, Macedonia, and Portuguese territories.

  • ACCESSWIRE

    Investors Eyeing New Trends in Biopharma & Healthcare: Stocks Heading Higher

    CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / The recent boom for things like medical marijuana in the UK as well as the rise of healthcare technology have investors interested in new and exciting companies. Recent developments across both sectors have new companies targeting expanded market share. Technology has become a major part of the healthcare industry, as we know it.

  • Innovative Cannabis Delivery Technologies on the Rise: The Greater Cannabis Company, Inc. (OTC: GCAN), Aphria, Tilray, Aurora and Canopy Growth
    GlobeNewswire

    Innovative Cannabis Delivery Technologies on the Rise: The Greater Cannabis Company, Inc. (OTC: GCAN), Aphria, Tilray, Aurora and Canopy Growth

    Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks releases a sector snapshot with a focus on new and innovative delivery systems coming to market. Through the month of September, larger Canadian cannabis companies including Aphria Inc. (TSX: APH), which commences trading on the NYSE today (NYSE:APHA), have been investing heavily in new cannabis delivery systems.

  • The Greater Cannabis Company to Update Shareholders on Corporate Strategy and Developments of Eluting Patch Platform (EPP) for Cannabinoid Use
    GlobeNewswire

    The Greater Cannabis Company to Update Shareholders on Corporate Strategy and Developments of Eluting Patch Platform (EPP) for Cannabinoid Use

    The Greater Cannabis Company, Inc. (GCAN) (“the Company”), a biopharmaceutical company focused on development and commercialization of innovative delivery systems for the Cannabis market, would like to update shareholders on its objectives and roadmap to achieving long term success. The Company has completed development and reformulation of its eluting patch (EPP) for cannabinoid use. In preparation for commercializing cannabinoid products, the Company completed extensive testing of its new formulations.